Scholarlink

<p>Despite the overall positive outcomes in hospitalization and mortality rates from the COVID-19 vaccines, COVID-19 infections remained prevalent around the world highlighting the need for alternative control strategies. Passive immunization with chicken IgY has long served as a feasible countermeasure, which gained further popularity in the research community during the recent pandemic. Here we demonstrate for the first time the scalability of anti-COVID-19 IgY production for effective distribution and potential use in large populations. Over 70,000 chickens were immunized against the SARS-CoV-2 S1 antigen to produce eggs containing anti-S1 IgY. The resulting egg yolk powder was formulated into commercially acceptable tablets for human consumption. QC and stability testing showed that the purified IgY and tablets maintained activity and stability for over a year. The resulting large batch of IgY tablets demonstrated equal immunoreactivity and virus neutralization potential against all leading COVID-19 variants. Our results demonstrate the feasibility of manufacturing egg yolk powder into edible tablets, and that can now be employed to block viral infectivity and transmission against all major COVID-19 variants affordably and effectively in both developed and developing countries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mass production of IgY-containing tablets for COVID-19 transmission control

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月11日

查看全文
  • Michelle Hawkins,
  • Brian Robley,
  • Farhang Alem,
  • Aarthi Narayanan,
  • Philip Larson,
  • Jason Hull,
  • Isabella Hajduk,
  • Michael Wallach

摘要

Despite the overall positive outcomes in hospitalization and mortality rates from the COVID-19 vaccines, COVID-19 infections remained prevalent around the world highlighting the need for alternative control strategies. Passive immunization with chicken IgY has long served as a feasible countermeasure, which gained further popularity in the research community during the recent pandemic. Here we demonstrate for the first time the scalability of anti-COVID-19 IgY production for effective distribution and potential use in large populations. Over 70,000 chickens were immunized against the SARS-CoV-2 S1 antigen to produce eggs containing anti-S1 IgY. The resulting egg yolk powder was formulated into commercially acceptable tablets for human consumption. QC and stability testing showed that the purified IgY and tablets maintained activity and stability for over a year. The resulting large batch of IgY tablets demonstrated equal immunoreactivity and virus neutralization potential against all leading COVID-19 variants. Our results demonstrate the feasibility of manufacturing egg yolk powder into edible tablets, and that can now be employed to block viral infectivity and transmission against all major COVID-19 variants affordably and effectively in both developed and developing countries.